ReShape Lifesciences receives NIH supplementary grant with CARSS

ReShape Lifesciences (RSLS) announced that the Company was awarded an approximately $241,000 supplementary grant from the National Institutes of Health, NIH, with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems, CARSS, for the development of the next-generation electrodes for ReShape’s Diabetes Bloc-Stim Neuromodulation, DBSN, device. The DBSN utilizes its proprietary vagus nerve block technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity. The supplementary grant will be utilized to conduct minimally invasive laparoscopic surgical electrode implantation techniques as well as long duration safety and blood glucose modulation experiments in a porcine model of diabetes.